Oncology Institute, Inc. ( (TOI) ) has released its Q2 earnings. Here is a breakdown of the information Oncology Institute, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The Oncology Institute, Inc. (TOI) is a leading value-based community oncology group in the United States, providing specialized cancer care and clinical trials across multiple states. In its second quarter of 2025, TOI reported a robust 21.5% increase in revenue compared to the previous year, driven by significant growth in its pharmacy business and the expansion of its value-based care model. The company also announced strategic expansions in Florida and Nevada, which are expected to further enhance its market presence.
Key financial highlights for the quarter include a consolidated revenue of $119.8 million and a gross profit increase of 34.4% to $17.5 million. Despite a net loss of $17.0 million, the company improved its Adjusted EBITDA to $(4.1) million from $(8.7) million in the same quarter last year. The addition of over 50,000 new capitated lives and record-setting performance in its retail pharmacy and dispensary segments were major contributors to this growth.
TOI’s operational strategy includes expanding its partnerships with major health plans, which is anticipated to double the number of lives covered in certain regions. The company also welcomed new leadership with the appointments of Dr. Jeff Langsam as Chief Clinical Officer and Kristin England as Chief Administrative Officer, aiming to strengthen its clinical and administrative operations.
Looking ahead, The Oncology Institute reaffirms its full-year 2025 guidance, projecting revenue between $460 million and $480 million and gross profit between $73 million and $82 million. The company remains optimistic about achieving the higher end of its revenue guidance and expects to reach Adjusted EBITDA positivity by the end of the year, subject to market conditions and operational developments.